TRIANGLE PHARMACEUTICALS - 500 Beiträge pro Seite

[southbound]

TRIANGLE PHARMACEUTICALS(VIRS): folgende News haben diesen Wert am Freitag um 22% anziehen lassen. Ich werde ihn meiner spekulativen WL für nächste Woche hinzufügen.
Last: 3.22$
Spekulatives KZ mittelfristig: 4.5$
weitere Informationen:http://www.biospace.com/b2/company_profile.cfm?CompanyID=280…
Chart:




TRIANGLE PHARMACEUTICALS(VIRS) Announces $75 Million Private Placement Financing Led By Warburg Pincus



DURHAM, N.C., Aug. 24 /PRNewswire/ --

Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that it has entered into a definitive agreement to raise $75 million through the sale of 28,301,887 shares of common stock at $2.65 per share to Warburg Pincus Private Equity VIII, L.P. ("Warburg Pincus") and certain other investors. The sale of shares will take place at two separate closings with the second closing subject to shareholder approval and other customary closing conditions.

Commenting on the sale, Dr. David Barry, Chief Executive Officer of Triangle, said, "We expect that this substantial investment led by Warburg Pincus along with our current cash balance will provide funding for up to two years based on our projected cash usage. We also believe that as a sophisticated health care investor, Warburg Pincus will provide beneficial strategic input to the Company as we continue to develop our anti-viral portfolio."

"We believe that Triangle`s late-stage anti-viral compounds currently in development and its substantial drug development expertise make the Company a unique investment opportunity," said Jonathan S. Leff, managing director, Warburg Pincus. "Our significant equity commitment is designed to help the Company realize the tremendous commercial potential that exists in its product pipeline."

At the first closing, expected to occur later today, the Company will sell 9,628,002 shares of common stock to Warburg Pincus for gross proceeds of $25,514,205. The second closing for the remaining 18,673,885 shares is expected to occur immediately after stockholders approval of the issuance of the shares. Up to 5,660,377 of the shares to be issued in the second closing may be sold to investors other than Warburg Pincus.

The Company has agreed to file a registration statement for the resale of the shares to be purchased within 10 days of the stockholder meeting to be called to vote on the issuance of the shares at the second closing.

In conjunction with the financing, Triangle entered into agreements with shareholders of the Company who in the aggregate own approximately 32% of the Company`s common stock outstanding as of August 3, 2001. These stockholders have agreed to vote in favor of the issuance of shares at the second closing.

Also in conjunction with the financing, Mr. Leff and Stewart J. Hen, vice president, Warburg Pincus, will be elected to the Company`s Board of Directors.

Banc of America Securities LLC is serving as placement agent for this transaction.

Triangle Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the development of new antiviral drug candidates, with a particular focus on therapies for the human immunodeficiency virus (HIV) and hepatitis. Triangle`s proprietary drug candidates under development for HIV and/or hepatitis include Coviracil(R) (emtricitabine), Coactinon(R) (emivirine), amdoxovir and clevudine. Triangle is also developing immunotherapies for HIV and hepatitis in collaboration with Dynavax utilizing Dynavax` ImmunoStimulatory Sequence (ISS) technology. More information about Triangle`s portfolio, management and product development strategy is available on Triangle`s website at: http://www.tripharm.com.

With over $10 billion under management and a further $5 billion available to invest, Warburg Pincus is among the largest private equity investment firms in the world. The firm has invested more than $11 billion in over 400 companies over the past thirty years. One of the world`s leading direct equity investors in healthcare, Warburg Pincus has helped to build more than 40 biotechnology and biopharmaceutical companies spanning a broad range of technologies and stages of development. For further information, please visit www.warburgpincus.com.

Statements in this press release that are not historical facts are forward-looking statements and are subject to numerous risks and uncertainties, including the risk that the first or second closings may not occur if conditions to closing are not met. Additional risks include the fact that cash usage targets may not be met for a number of reasons, including the risk that unpredictable events or changes in our drug development strategies may impact the timing and degree of actual spending. Additionally, other risks include the fact that clinical trials for our drug candidates may not proceed as planned and regulatory submissions for those drug candidates may be delayed, the Company may be unable to successfully complete pivotal clinical trials or that its trials could be halted or terminated by regulatory authorities, regulatory submissions may be delayed, its inability to commercialize Coviracil, DAPD and ISS-based therapies due to patent rights held by third parties, the Company`s ability to obtain additional funding (including contingent contractual milestone payments), patent protection and required regulatory approvals for its drug candidates, the development of competitive products by others, the cost of coactive therapy and the extent to which coactive therapy achieves market acceptance, the Company`s success in identifying new drug candidates, acquiring rights to the candidates on favorable terms and developing any candidates to which the Company acquires any rights, and that the Company`s collaborations with third parties may not prove successful. These and other risks are discussed in detail from time to time in the Company`s filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those predicted in this press release. The Company disclaims any obligations to update any forward-looking statements in this press release.

[southbound]

Die Kursentwicklung ist ein sehr schönes Beispiel wie die großen Investoren die Kurse niederknüppeln um billig einzusteigen.
Übrigens:
Cash Per Share ($) 1.29
Book Value/Share ($) 0.51


Sale of 28,301,887 shares of common stock at $2.65 per share to Warburg Pincus Private Equity VIII, L.P. ("Warburg Pincus")

[trendwatcher]

Triangle hatte (nur ...) ein Cash-Problem.
Das scheint nun gelöst.

Der Aktienkurs war - wegen dieses Cash-Problems und der Marktentwicklung - ein Trauerspiel. Jetzt könnte er sich rasch wieder vervielfachen. Denn das Potential von Triangle ist interessant (siehe unten). Beachten: In Deutschland (bisher ...) kaum Umsätze.

trendwatcher

---------------

Clinical Development for Triangle Pharmaceuticals

Tradename Developer(s) Partners Indications Current Phase

Coactinon Abbott Laboratories
Triangle Pharmaceuticals
none HIV/AIDS
III

Coviracil Abbott Laboratories
Triangle Pharmaceuticals
none HIV/AIDS
III

DAPD Triangle Pharmaceuticals
Abbott Laboratories
HIV/AIDS
I/II

DMP-450 Triangle Pharmaceuticals
none HIV/AIDS
I/II
FTC Abbott Laboratories
Triangle Pharmaceuticals
none HIV/AIDS
unavailable

Immunostimulatory sequences Triangle Pharmaceuticals
Dynavax Technologies
none Hepatitis-B
I

Kaletra Abbott Laboratories
Triangle Pharmaceuticals
HIV/AIDS
Market

L-FMAU Triangle Pharmaceuticals
Abbott Laboratories
Hepatitis-B
I/II

[southbound]

Ja, die haben unter anderem ein`s auf den Zünder bekommen,
weil eine 5 mio$ ausgefallen war. Aber jetzt 75mio$!!

[southbound]

Ich glaube, wer sich morgen in D zeitig eindeckt, kann um 15.30 Uhr schon satt verkaufen.

[LipAir]

Hallo

Der Titel ist gut! Die nächsten Tagen werden Zeigen wie gut!!
So sprünge wie gestern + 35% könnten keine Ausnahme gewesen sein!!
Wichtig dabei ist was die neue Verwaltung von VIRS drauf hat...!

Wo sieht ihr das Kursziel für ende 2001?

Gruss

LipAir

[puhvogel]

Ich würde die an Deiner Stelle heute verkaufen , wenn Du kannst. Schua mal auf die Umsätze gestern.

[LipAir]

Hallo

Wie waren den die Umsätze gestern???

bin hoch drin....!!! 2 Stellig!!! :-(

gruss LipAir

[puhvogel]

2.Stellig? Mit einer Aktie?
Jedenfalls keine Panik!
Langfristig weiss ich eh nix genaues , aber ich glaube aufgrund der niedrigen Umsätze nicht, dass jemand gestern aus fundamentalem Interesse gekauft hat, sondern eher aus kosmetischen Gründen.

Aber es sah gestern zum Handelsende genau nach Window Dressing aus, und nicht nur bei VIRS (zB UTHR, AVAN, AMLN, TTP, aber bei VIRS war der Auschlag ohne News und ohne Umsätze besonders stark). Bei POZN kannst Du ein solches überproportionales Window dressing auch Ende Juni beobachten. Deshalb halte ich VIRS für heute für ein trading sell.
Entscheiden musst du aber selber.

[LipAir]

Hallo

Ja 2Stellig mit einer Aktie....und nicht Wenige....ICh war mal genau 102% im Plus war aber in den Ferien als ich zurück kamm 30- !!!!

Und nun warte ich auf bessre Zeiten.......oder Jahren...!

Glaubst du die kommen mal wieder auf 2Stellige Zahlen???

Gruss LipAir

[LipAir]

Hat irgend jemand auch diesen Titel???


:o)


(gibts doch gar nicht)

[trendwatcher]

@LipAir

Gibt´s doch ...

Bin (Käufe im August und September) im grünen Bereich und zuversichtlich:
Denn der Chart sieht gut aus und die Umsätze dürften (bei news) wieder anziehen.

trendwatcher

[LipAir]

HAllo

Was siehst du für einen Kursziel bis auf Ende Jahr??

Gruss LipAir

[southbound]

unter begrenzung trendkanal

WL reenter

[southbound]

NEW YORK, July 31 (Reuters) - Shares of Triangle Pharmaceuticals Inc. (NasdaqNM:VIRS - News) soared 30 percent on Wednesday after the drug developer said it had reacquired rights to four experimental drugs from Abbott Laboratories Inc. and would submit a marketing application for an HIV drug this quarter.




The company`s stock jumped 21 percent, or 50 cents, to $2.85 in morning trade on Nasdaq after reaching as high as $3.44.

The Durham, North Carolina-based company announced positive results from a late-stage clinical trial of Coviracil, one of the drugs reacquired from Abbott (NYSE:ABT - News).

Triangle said it would submit an application with the U.S. Food and Drug Administration in the third quarter of this year to market Coviracil.

The drug is among a class of treatments called nucleoside reverse transcriptase inhibitors, which are aimed at interfering with an enzyme that facilitates the genetic coding process the HIV and AIDS viruses use to make copies of themselves inside host human cells.

The company said interim results from the 48-week trial of 571 patients showed that Coviracil was statistically superior to the comparison drug in achieving primary and secondary targets for safety and efficacy.

As a result, a data safety monitoring board recommended that all patients in the trial be offered the experimental drug, Triangle said.

The company said it and Abbott made a "mutual decision" for Triangle to reacquire full rights to Coviracil, amdoxovir for HIV and clevudine for hepatitis B. The companies had agreed in 1999 to develop the products and split future profits.

The deal benefits Abbott because the drugmaker gets to keep all revenue from its hot-selling AIDS drug Kaletra and focus on the class of drugs to which Kaletra belongs, called protease inhibitors.

Triangle, meanwhile, can sell its own drug, if approved, without having to worry about Abbott sales representatives being distracted by marketing protease inhibitors, according to analyst David Bouchey from C.E. Unterberg, Towbin.

"If you`re Triangle and you have reverse transcriptase inhibitors, are you really get into the salesperson`s bag?" he said.

Bouchey said Coviracil, which Triangle is also testing to treat Hepatitis B, could eventually fetch annual sales of between $400 million and $500 million.

He noted that Phase III clinical trials of Coviracil have proved the drug does not create as much resistance as other HIV and AIDS treatments.

"Patients have been shown not to generate as many mutations that would make them resistant to the drug," he said.

[FLOTSAM_AND_JETSAM_US]

Neues zu Coviracil


Coviracil(R) NDA for the Treatment of HIV Disease Accepted by the Food and Drug Administration
Monday November 4, 8:06 am ET


DURHAM, N.C., Nov. 4, 2002 /PRNewswire-FirstCall/ --
Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS - News) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for marketing approval of Coviracil for the treatment of HIV disease has been accepted for filing. Filing of the NDA is recognition by the FDA that the application is sufficiently complete for review.




"We are very pleased with this notification," commented Daniel G. Welch, Chairman and Chief Executive Officer of Triangle. He continued, "Consistent with our previous guidance when we submitted our NDA, the FDA granted Coviracil a standard review. This means that as early as the third quarter of 2003, we hope to have our first NDA approved. We believe, once approved, Coviracil will offer patients and physicians an important new medicine for the management of HIV disease. We will now turn our efforts to completion of the review process with the FDA to work towards the timely approval of Coviracil."

Coviracil is a potent, once-a-day Nucleoside Reverse Transcriptase Inhibitor (NRTI). The NDA includes data from over 2,000 patients and is supported by two pivotal trials, FTC-303 and FTC-301. Triangle expects to file a European Marketing Authorisation Application (MAA) by December 31, 2002.

[southbound]

17 millionen shares, aber hallo!